3 reasons clinicians should participate in clinical data registries healthcaredive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healthcaredive.com Daily Mail and Mail on Sunday newspapers.
(BPT) - Arthritis is a common health condition in the United States, affecting one in four adults according to the Centers for Disease Control and Prevention. Characterized by the inflammation
Do you Have Arthritis? Consider These Changes flcourier.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from flcourier.com Daily Mail and Mail on Sunday newspapers.
Which audits are affected?
ISA (UK) 701 (Revised November 2019) (Updated January 2020) applies to audits of listed entities, non-listed public interest entities, entities that are required, and those that choose voluntarily to report on how they have applied the UK Corporate Governance Code, where the auditor is required by law or regulation to communicate key audit matters in the auditor’s report, as well as where the auditor voluntarily chooses to do so.
Audit report implications
Previously, auditors were required to provide an explanation of how they had applied the concept of materiality in planning and performing an audit and they had to specify the overall materiality threshold used (ie materiality for the financial statements as a whole). These disclosures may have included the threshold for performance materiality though this was not a requirement.
In CheckMate -577, Opdivo
1
Approval expands the role of Opdivo in earlier stages of disease, with two indications in the adjuvant setting across three types of cancer
1
PRINCETON, NJ, USA I May 20, 2021 I Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved
Opdivo
® (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).
1 The approval is based on results from the Phase 3 CheckMate -577 trial that evaluated
Opdivo (n=532) compared to placebo (n=262) in esophageal or GEJ cancer patients with residual pathologic disease following neoadjuvant CRT and complete resection.